The National Cancer Institute (NCI) in partnership with the National Institute of Allergy and Infectious Disease is seeking community input on research approaches and priorities related to SARS-CoV-2 serology. In this Request for Information, NCI seeks comments on any or all of, but not limited to, the following research topics related to serology: 1. Research […]
Designated COVID-19 Section on the B-T.CR Forum
Sharing is caring. This has become a key phrase during the COVID-19 pandemic. The AIRR Community proudly announces a designated channel in our data discussion forum B-T.CR (www.b-t.cr). This public resource will list all current and upcoming studies with immune repertoire data on COVID-19. If you happen to stumble upon AIRR-seq or single cell RNA-seq […]
Coronavirus in the crosshairs, Part 8: FDA’s Emergency Use Authorization of Therapeutics
During public health emergencies, the U.S. Food and Drug Administration (FDA) can allow use of unapproved medical products or unapproved uses of approved medical products to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by threat agents, such as SARS-CoV-2, when there are no adequate, approved, and available alternatives. On March 27, […]
Coronavirus in the crosshairs, Part 7: Diagnostic tests
Post written by Simon L. Goodman, D.Phil., Science & Technology Program Manager, The Antibody Society With no foreseeable safe or effective therapy or vaccine against SARS-CoV-2, extensive population testing and quarantine are amongst the few scientifically rational means of protecting people and monitoring the pandemic. To date (April 26, 2020) only 26.6 million tests for […]
FDA approves sacituzumab govitecan (Trodelvy®) for triple-negative breast cancer
On April 22, 2020, the US Food and Drug Administration (FDA) granted an accelerated approval to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of patients with metastatic triple-negative breast cancer who received at least two prior treatments for metastatic disease. Sacituzumab govitecan is composed of an anti-TROP-2 humanized IgG1 antibody conjugated to the topoisomerase inhibitor SN38, […]
